购物车
- 全部删除
您的购物车当前为空
Proadrenomedullin (1-20), human
还可以产品编号 TP1490Cas号 150238-87-2
Endogenous peptide agonist of Mas related GPR X2 (MRGPRX2, EC50 = 251 nM). Also a noncompetitive nicotinic cholinergic antagonist. Inhibits nicotine-stimulated catecholamine secretion from PC12 cells in vitro, and from sympathetic nerve endings and adrenal chromaffin cells in vivo. Corresponds to amino acids 1 - 20 of proadrenomedullin. Antihypertensive.
Proadrenomedullin (1-20), human
还可以产品编号 TP1490Cas号 150238-87-2
Endogenous peptide agonist of Mas related GPR X2 (MRGPRX2, EC50 = 251 nM). Also a noncompetitive nicotinic cholinergic antagonist. Inhibits nicotine-stimulated catecholamine secretion from PC12 cells in vitro, and from sympathetic nerve endings and adrenal chromaffin cells in vivo. Corresponds to amino acids 1 - 20 of proadrenomedullin. Antihypertensive.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 3,620 | 35日内发货 |
大包装 & 定制
加入购物车
实验操作小课堂
查看更多 联系我们获取更多批次信息
资源下载
产品介绍
生物活性
化学信息
| 产品描述 | Endogenous peptide agonist of Mas related GPR X2 (MRGPRX2, EC50 = 251 nM). Also a noncompetitive nicotinic cholinergic antagonist. Inhibits nicotine-stimulated catecholamine secretion from PC12 cells in vitro, and from sympathetic nerve endings and adrenal chromaffin cells in vivo. Corresponds to amino acids 1 - 20 of proadrenomedullin. Antihypertensive. |
| 分子量 | 2460.84 |
| 分子式 | C112H178N36O27 |
| CAS No. | 150238-87-2 |
| 密度 | 1.31g/cm3 |
储存&溶解度
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
计算器
体内实验配液计算器
请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：
比如您的给药剂量是 10 mg/kg ，每只动物体重 20 g ，给药体积 100 μL ， 
剂量转换
对于不同动物的给药剂量换算，您也可以参考 更多
评论列表
预览
Related Tags: buy Proadrenomedullin (1-20), human | purchase Proadrenomedullin (1-20), human | Proadrenomedullin (1-20), human cost | order Proadrenomedullin (1-20), human | Proadrenomedullin (1-20), human chemical structure | Proadrenomedullin (1-20), human formula | Proadrenomedullin (1-20), human molecular weight
嗨！很高兴为您提供帮助！
评论内容